• Kyodo News


Swiss drug maker Novartis will begin conducting a clinical test Wednesday in Kagoshima Prefecture to confirm the safety and effectiveness of its H1N1 swine flu vaccine, sources familiar with the matter said Saturday.

The test, which will involve about 200 healthy adults in the first stage and around 100 children later, is being conducted so it can export the vaccine to Japan, the sources said.

Unable to view this article?

This could be due to a conflict with your ad-blocking or security software.

Please add japantimes.co.jp and piano.io to your list of allowed sites.

If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.

We humbly apologize for the inconvenience.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.